ScholarIQanswers from OpenAlex & ORCID
David Gruben
ResearcherPublications, citations & collaboration network
David Gruben is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David Gruben have?
ScholarIQindexed works
David Gruben has 168 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David Gruben have?
ScholarIQcitation count
David Gruben has 8,195 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David Gruben?
ScholarIQh-index
David Gruben has an h-index of 33 in OpenAlex.
What is the i10-index of David Gruben?
ScholarIQi10-index
David Gruben has an i10-index of 56 in OpenAlex.
What is the ORCID of David Gruben?
ScholarIQorcid
The ORCID for David Gruben is on the source record.
What is the OpenAlex record for David Gruben?
ScholarIQopenalex
The OpenAlex for David Gruben is on the source record.
What are the most-cited papers on David Gruben?
ScholarIQmost cited works
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann, Joel M. Kremer, John J. Cush, Hendrik Schulze‐Koops, Carol A. Connell, John Bradley, David Gruben, Gene V. Wallenstein, Samuel H. Zwillich, Keith S. Kanik
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, Juan A. García Meijide, Sylke Wagner, Šárka Forejtová, Samuel H. Zwillich, David Gruben, Tamás Koncz, Gene V. Wallenstein, Sriram Krishnaswami, John Bradley, Bethanie Wilkinson
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Eun Bong Lee, Roy Fleischmann, Stephen Hall, Bethanie Wilkinson, John Bradley, David Gruben, Tamás Koncz, Sriram Krishnaswami, Gene V. Wallenstein, Chuanbo Zang, Samuel H. Zwillich, Ronald van Vollenhoven
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R Burmester, Ricardo Blanco, Christina Charles‐Schoeman, J. Wollenhaupt, Cristiano A. F. Zerbini, Birgitta Benda, David Gruben, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, Tamás Koncz, Koshika Soma, John Bradley, Charles A. Mebus
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, Edward Keystone, Joel M. Kremer, Cristiano A. F. Zerbini, Myrna Cardiel, Stanley Cohen, Peter Nash, Yeong Wook Song, Dana Tegzová, Bradley T. Wyman, David Gruben, Birgitta Benda, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, John Bradley, Carol A. Connell, and the ORAL Scan Investigators